Testing version — LOERadar is in active testing. Features and data may change.
CYMBALTA (DULOXETINE HYDROCHLORIDE) | LOERadar
CYMBALTA
NDA
DULOXETINE HYDROCHLORIDE | N021427 | ELI LILLY AND CO
3 strengths0 unique patents0 unique exclusivities
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
Para IV certification filed but no ANDA patent litigation cases (NOS 835) matched from PACER. Litigation may be pending or filed under a different caption.
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (3)
Sort:
#001 — EQ 20MG BASE
RLD
0 patents0 exclusivities▴
CAPSULE, DELAYED REL PELLETS;ORAL | Approved: Aug 3, 2004
No patent or exclusivity listings for this strength.
#002 — EQ 30MG BASE
RLD
0 patents0 exclusivities▾
CAPSULE, DELAYED REL PELLETS;ORAL | Approved: Aug 3, 2004
#004 — EQ 60MG BASE
RLD
0 patents0 exclusivities▾
CAPSULE, DELAYED REL PELLETS;ORAL | Approved: Aug 3, 2004